MT3

About MT3

Malignant Tumor Treatment Technologies, Inc. (MT3) is a pioneering company in the field of cancer treatment, focusing on the development of novel anticancer agents and advanced imaging technologies. The company primarily serves healthcare providers, veterinarians, and pet owners, offering solutions that improve the efficacy of tumor treatments. Operating in the oncology market, MT3's business model revolves around research and development (R&D), clinical trials, and the commercialization of its proprietary technologies. Revenue is generated through the sale of its anticancer agents, licensing agreements, and partnerships with medical institutions and pharmaceutical companies. MT3's flagship product, SQAP, is a novel anticancer agent that binds to focal adhesion kinase, modulating its activity to enhance the effectiveness of radiation therapy. The company also conducts multimodal molecular imaging studies to evaluate pharmacological alterations in the tumor microenvironment, aiming to improve radiation response. MT3's innovative approach and commitment to advancing cancer treatment have earned it recognition, including the Japan Venture Awards.